---
schema_version: "secwatch.filing_event.v1"
accession: "0001110803-26-000014"
form_type: "8-K"
ticker: "ILMN"
cik: "0001110803"
company_name: "ILLUMINA, INC."
filed_at: "2026-01-30T23:59:59+00:00"
generated_at: "2026-05-16T05:53:52.027034+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Illumina completes $350M acquisition of SomaLogic from Standard BioTools

## Summary
- Purchase price $350M in cash plus up to $75M in performance milestones and royalties.
- SomaLogic's proteomics tech (SomaScan, SomaSignal) expands Illumina's multiomics portfolio.
- Acquisition funded with cash on hand; financial impact discussed on Feb 5, 2026 earnings call.
- Builds on co-development partnership established in 2021 for NGS-based proteomics.

## SEC filing metadata
- accession: 0001110803-26-000014
- form_type: 8-K
- ticker: ILMN
- cik: 0001110803
- company_name: ILLUMINA, INC.
- filed_at: 2026-01-30T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1110803/000111080326000014/0001110803-26-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1110803/000111080326000014/ilmn-20260130.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001110803-26-000014
- JSON: https://secwatch.observer/filing/0001110803-26-000014.json
- Plain text: https://secwatch.observer/filing/0001110803-26-000014.txt

## Source-grounded claims
- claim_id: 6f47cf92aab3960a69a7cfbaa454daff445eb279
  claim: ILLUMINA, INC. completed an acquisition involving Standard BioTools Inc. for $350,000,000 in cash (closed 2026-01-30).
  evidence_excerpt: BioTools’s mass cytometry and microfluidics businesses (the “Business”). On January 30, 2026, the Company completed the Transaction. The Company paid a purchase price of $350,000,000 in cash, subject to customary adjustments. The Purchase Agreement further provides for, in connection with the revenues generated from certain products and services, (i) royalty
  evidence_url: https://www.sec.gov/Archives/edgar/data/1110803/000111080326000014/0001110803-26-000014-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.